MONASH IVF GROUP LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.42 AUD | -.--% |
|
+1.43% | +9.23% |
| Apr. 30 | Wilsons Upgrades Monash IVF to Overweight from Market-Weight, Price Target is AU$1.58 | MT |
| Apr. 12 | RBC Capital Markets Starts Monash IVF Group at New Sector Perform, Price Target is AU$1.50 | MT |
| Sales 2024 * | 254M 169M | Sales 2025 * | 274M 182M | Capitalization | 553M 368M |
|---|---|---|---|---|---|
| Net income 2024 * | 27M 17.96M | Net income 2025 * | 32M 21.29M | EV / Sales 2024 * | 2.34 x |
| Net Debt 2024 * | 41.72M 27.75M | Net Debt 2025 * | 31.24M 20.78M | EV / Sales 2025 * | 2.13 x |
| P/E ratio 2024 * |
20.3
x | P/E ratio 2025 * |
16.9
x | Employees | 867 |
| Yield 2024 * |
3.53% | Yield 2025 * |
4.18% | Free-Float | 92.72% |
More Fundamentals
* Assessed data
More news
Latest transcript on Monash IVF Group Limited
More recommendations
| 1 week | +1.43% | ||
| 1 month | -3.07% | ||
| 3 months | -4.05% | ||
| 6 months | +9.23% | ||
| Current year | +9.23% |
1 week
1.39
1.45
1 month
1.391.53
Current year
1.291.53
1 year
1.111.53
3 years
0.801.53
5 years
0.381.54
10 years
0.382.55
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Knaap
CEO | Chief Executive Officer | - | 15-08-30 |
Malik Jainudeen
DFI | Director of Finance/CFO | - | 14-03-31 |
Thierry Panthier
CTO | Chief Tech/Sci/R&D Officer | - | 19-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Neil Broekhuizen
BRD | Director/Board Member | 58 | 14-06-03 |
Richard Davis
CHM | Chairman | 68 | 14-06-03 |
Richard Henshaw
BRD | Director/Board Member | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1.42 | -.--% | 826,645 |
| 24-05-30 | 1.42 | -2.07% | 351,869 |
| 24-05-29 | 1.45 | +1.05% | 691,155 |
| 24-05-28 | 1.435 | +1.41% | 400,748 |
| 24-05-27 | 1.415 | +1.07% | 580,218 |
Delayed Quote Australian S.E., May 31, 2024 at 02:10 am EDT
More quotes
Monash IVF Group Limited is an Australia-based company, which is primarily involved in assisted reproductive services. The Company is also a provider of specialist womenâs imaging services. It operates through two segments: Monash IVF Group Australia and Monash IVF Group International. The Monash IVF Group Australia segment provides assisted reproductive services, ultrasound, and other related services. The Monash IVF Group International segment provides assisted reproductive services in Southeast Asia. The Company's business includes Fertility Solutions that provide fertility treatment and care; KL Fertility is a fertility specialist center; Monash IVF is a fertility research and treatment center; Monash IVF KPJ Johor is a full-service hospital-based fertility center, and Monash Ultrasound for Women provides tertiary level prenatal diagnostic services. Its business also includes Repromed and Sydney Ultrasound for Women.
Calendar
2024-08-21
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.42
AUD
Average target price
1.541
AUD
Spread / Average Target
+8.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.23% | 368M | |
| +25.52% | 87.77B | |
| -24.52% | 70.35B | |
| -5.56% | 25.03B | |
| +4.31% | 17.73B | |
| -14.25% | 16.31B | |
| +2.97% | 15.48B | |
| +70.11% | 13.52B | |
| +79.20% | 13.01B | |
| +40.44% | 12.9B |
- Stock Market
- Equities
- MVF Stock
